Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Grillo is active.

Publication


Featured researches published by S. Grillo.


Helicobacter | 2017

New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.

Antonio Tursi; Francesco Di Mario; Marilisa Franceschi; Rudi De Bastiani; Walter Elisei; G. Baldassarre; A. Ferronato; S. Grillo; S. Landi; Maria Zamparella; Manuela De Polo; Laura Boscariolo; Marcello Picchio

Rising antibiotic resistance requires the evaluation of new and effective therapies.


Journal of Clinical Gastroenterology | 2016

A Primary-Care Interventional Model on the Diverticular Disease: Searching for the Optimal Therapeutic Schedule.

Angelo Campanini; Umberto De Conto; Francesco Cavasin; Fernanda Bastiani; Antonio Camarotto; Luigi Gardini; Alessandra Geremia; Cristina Marastoni; Carlo Missorini; Elena Quarantelli; Umberto Sassi; Francesco Scarabello; Nadia Dal Bò; Matteo Riccò; S. Grillo; S. Landi; Francesco Di Mario

Introduction In routine colonoscopy, diverticulosis is the most commonly found feature, but only a minority of these cases show symptoms of diverticular disease. From June 2014 to December 2014, we enrolled prospectively 178 patients affected by symptomatic uncomplicated diverticular disease (Male/Female=0.47, mean age 71.7±11.5 y, range 41 to 95 y) from 15 General Pratictioners patient files. All patients were symptomatic; in all cases, diagnosis was been confirmed by a colonoscopy performed at least 1 year before. Patients with acute diverticulitis were excluded. On the basis of the predominant symptoms (abdominal complaints or constipation), patients were addressed to 4 different therapeutic approaches using mesalamine, rifaximine, probiotics (in a consortium of different species of Lactobacillus and Bifidobacterium), and fibers (Plantago Ovata Husk). All treatments lasted 3 months. Results: Sixty-three patients were enrolled in group A (rifaximine), 43 in group A1 (rifaximine+fibers+probiotics), 23 in group B (mesalamine), and 31 in group B1 (mesalamine+fibers). Analysis of variance suggested a statistically significant difference (P<0.003) among groups at the end of the observation period, with Groups A1 and B1 showing a higher number of bowel movement per week. Global linear measurement confirmed the role of treatment as a significant factor (F=2.858; P=0.039) associated with body mass index (F=6.972; P<0.009). Conclusions: In accordance with the baseline clinical presentation, the supplementation of fiber and/or probiotics is associated with a statistically significant improvement in the clinical pattern of symptoms in patients with diverticular disease in a primary-care/family physician setting.


Digestive and Liver Disease | 2018

P.01.12 FREQUENCY OF DIAGNOSIS OF ATROPHIC GASTRITIS IN A PRIMARY CARE SETTING: A POPULATION STUDY ON 10,000 PEOPLE

F. Di Mario; S. Landi; S. Grillo; C. Miraglia; Pellegrino Crafa; M. Franceschi; R. Cannizzaro; G. Baldassare; O. Cavatorta; L. Franzoni; N. Dal Bò; Carmelo Scarpignato; Massimo Rugge


Digestive and Liver Disease | 2018

P.07.5 SMOKER AND EX-SMOKER PATIENTS AFFECTED BY CROHN'S DISEASE: ARE THEY SO DIFFERENT?

S. Grillo; G. Zerboni; S. Landi; N. Mezzina; D. Reiteri; A. Dell'Era; S. Carmagnola; A. Massari; A. Cassinotti; P. Molteni; F. Di Mario; S. Ardizzone; G. Maconi


Digestive and Liver Disease | 2018

P.02.18 ROLE, EFFICACY AND SAFETY OF BUDESONIDE-MMX IN ULCERATIVE COLITIS IN REAL LIFE. A STUDY IN A THIRD-LEVEL CENTER

S. Landi; N. Mezzina; S. Carmagnola; S. Grillo; A. Massari; A. Cassinotti; A. Dell'Era; P. Molteni; F. Di Mario; S. Ardizzone; G. Maconi


Digestive and Liver Disease | 2018

P.02.1 VEDOLIZUMAB IN IBD: EARLY RESPONSE AS A PROGNOSTIC FACTOR

N. Mezzina; Andrea Cassinotti; S. Carmagnola; A. Massari; S. Landi; S. Grillo; G. Maconi


Digestive and Liver Disease | 2018

P.06.23 EARLY GERD RELAPSE: A PROSPECTIVE ONE YEAR STUDY BY MEANS OF A NON-INVASIVE SURROGATE TEST

M. Franceschi; S. Speroni; S. Grillo; M. Capasso; C. Miraglia; V. Corrente; Pellegrino Crafa; L. Franzoni; Carmelo Scarpignato; E. Savarino; N. De Bortoli; F. Di Mario


Digestive and Liver Disease | 2018

P.07.22 ANTI-TNF-ALFA SECOND-LINE INFLIXIMAB THERAPY IN PATIENTS AFFECTED BY CROHN'S DISEASE AND ULCERATIVE COLITIS: WHO AND HOW RECOVERS REMISSION?

S. Grillo; N. Mezzina; S. Landi; A. Massari; E. Grassi; A. Dell'Era


Gastroenterology | 2017

Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard

Edoardo Savarino; Nicola de Bortoli; Marco Della Coletta; Silvia Speroni; S. Grillo; A. Bertelè; Nadia Dal Bo; Carmelo Scarpignato; Francesco Di Mario


Gastroenterology | 2017

Recovery of Gastric Function in Chronic Atrophic Gastritis By Using L-Cysteine: A 3 Years Study

S. Grillo; S. Landi; C. Miraglia; Matteo Riccò; Giuseppe Grande; Marilisa Franceschi; A. Antico; R. Cannizzaro; Carmelo Scarpignato; Massimo Rugge; Francesco Di Mario

Collaboration


Dive into the S. Grillo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Antonio Tursi

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Marilisa Franceschi

Casa Sollievo della Sofferenza

View shared research outputs
Researchain Logo
Decentralizing Knowledge